AbbVie Clinical Trials
Sponsors / AbbVie
1,152 ClinicalTrials.gov entries name AbbVie as the lead sponsor. The portfolio currently includes 183 recruiting studies, 141 active non-recruiting studies, and 663 completed studies. 103 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include business or strategic decisions, safety concerns. Cumulative planned enrollment across all listed trials is 560,066 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
1,152
Total Trials
183
Recruiting
141
Other Active
663
Completed
103
Terminated / Withdrawn
560,066
Total Enrollment
Termination reasons: Business49% · Other16% · Safety11% · Recruitment10% · Efficacy8% · Regulatory3% · Funding3% · PI/or_Site2%
Recent Terminations
- Solid Tumors"Strategic considerations"
- Major Depressive Disorder (MDD)"Company Decision"
- Human Immuno-deficiency Virus (HIV) Disease"Company Decision"
- Healthy Volunteer"Strategic considerations"
- Ulcerative Colitis"Sponsor Decision\_Not Safety Related"
- Acute Myeloid Leukemia"Strategic considerations"
- Alzheimer's Disease"Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints."
- Drug-resistant Focal Seizure"Failure to recruit subjects."
- Upper Limb Spasticity"Strategic considerations"
- Healthy Volunteers"Strategic considerations"
Active Trials (141 total)
- NCT05978622
- NCT06125795
- NCT06390319
- NCT04608318
- NCT04898894
- NCT05183035
- NCT05833438
- NCT04704921
- NCT05843643
- NCT05995340
- NCT06107426
- NCT07136103
- NCT07413133
- NCT07414784
- NCT07502417
- NCT05821855
- NCT06462235
- NCT07040319
- NCT07097363
- NCT07419347